Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05057702 · ClinicalTrials.gov registry record · NA
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
A NA study of Medulloblastoma and Ependymoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 74
- Enrollment target
- 8
- Study locations
NCT05057702 is a NA study of Medulloblastoma and Ependymoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 74 participants, below the 138-participant average among 29 other Medulloblastoma trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05057702, a NA study of Medulloblastoma and Ependymoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
- 8
- Study locations
Study Summary
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.
Conditions Studied
Interventions
- OTHER Specialized Tumor Board Treatment Plan
- OTHER Combinations
Study Locations (8)
California
- Children's Hospital of Los Angeles - Los Angeles
- Rady Children's Hospital - San Diego
- University of California, San Francisco - San Francisco
New York
- New York University - New York
- Columbia University Medical Center - New York
District of Columbia
- Children's National Hospital - Washington D.C.
Missouri
- St. Louis Children's Hospital / Washington University in St. Louis - St Louis
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-02-22 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05057702
The ClinicalTrials.gov registry entry for NCT05057702 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 29 other Medulloblastoma trials with a reported enrollment target (46% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Medulloblastoma appearing as the primary indexed condition, and to 2 interventions - of which Specialized Tumor Board Treatment Plan is the first listed.
NCT05057702 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, New York, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05057702 about?
NCT05057702 is a clinical study titled "Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma". The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma...
What is the current status of trial NCT05057702?
This trial is currently recruiting. It is a NA study. The enrollment target is 74 participants. The study started on 2022-02-22. Estimated completion is 2028-01-31.
What conditions does trial NCT05057702 study?
This clinical trial studies the following conditions: Medulloblastoma, Ependymoma, Medulloblastoma Recurrent, Medulloblastoma, Childhood, Ependymoma Malignant.
What interventions are being tested in trial NCT05057702?
The interventions under investigation include: Specialized Tumor Board Treatment Plan (OTHER), Combinations (OTHER).
Who is sponsoring clinical trial NCT05057702?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05057702 being conducted?
This trial has 8 study locations across California, District of Columbia, Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
COMPLETED · NA
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RECRUITING · Phase 1
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.